Table 2.
Onset symptoms to hospital admission and laboratory data of patients with epilepsy and COVID-19.
| Total |
NS group |
RS group |
EH group |
P | |
|---|---|---|---|---|---|
| N = 30 | N = 13 (43.3%) | n = 10 (33.3%) | n = 7 (23.3%) | ||
| Onset symptoms to hospital admission | |||||
| Typical symptoms | |||||
| Fever | 18 (60%) | 9 (69.2%) | 5 (50%) | 4 (57.1%) | 0.641 |
| Cough | 8 (26.7%) | 3 (23.1%) | 2 (20%) | 3 (42.9%) | 0.659 |
| Expectoration | 4 (13.3%) | 3 (23.1%) | 1 (10%) | 0 (0%) | 0.523 |
| Dyspnea | 5 (16.7%) | 3 (23.1%) | 2 (20%) | 0 (0%) | 0.572 |
| Chest distress | 5 (16.7%) | 1 (7.7%) | 3 (30%) | 1 (14.3%) | 0.396 |
| Chest pain | 3 (10%) | 1 (7.7%) | 2 (20%) | 0 (0%) | 0.584 |
| Fatigue | 13 (43.3%) | 8 (61.5%) | 4 (40%) | 1 (14.3%) | 0.134 |
| Vomiting | 11 (36.7%) | 7 (53.8%) | 4 (40%) | 0 (0%) | 0.054 |
| Neurological symptoms | |||||
| Seizure | 3 (10%) | 1 (7.7%) | 2 (20%) | 0 (0%) | 0.584 |
| Headache | 8 (26.7%) | 4 (30.8%) | 4 (40%) | 0 (0%) | 0.211 |
| Dizziness | 4 (13.3%) | 3 (23.1%) | 1 (10%) | 0 (0%) | 0.523 |
| Impaired consciousness | 11 (36.7%) | 5 (38.5%) | 5 (50%) | 1 (14.3%) | 0.356 |
| Language disorder or aphasia | 10 (33.3%) | 6 (46.15%) | 3 (30%) | 1 (14.3%) | 0.761 |
| Activity obstacle or paralysis | 9 (30%) | 4 (30.8%) | 4 (40%) | 1 (14.3%) | 0.463 |
| Numness of the limbs | 3 (10%) | 2 (15.4%) | 1 (10%) | 0 (0%) | 0.776 |
| Gatism | 3 (10%) | 1 (7.7%) | 2 (20%) | 0 (0%) | 0.584 |
| No above neurological symptoms | 13 (43.3%) | 4 (30.8%) | 3 (30%) | 6 (85.7%) | 0.052 |
| Laboratory data | |||||
| White blood cell, (3.5–9.5)×109/L | 6.97 (5.11,12.44) | 6.97 (5.05,14.6) | 7.23 (5.07,12.45) | 6.97 (4.41,7.95) | 0.748 |
| Neutrophil count1, (1.8–6.3)×109/L | 4.9 (3.45,9.73) | 5.56 (3.88,12.9) | 4.82 (3.33,10.16) | 4.58 (3.0,5.86) | 0.462 |
| Lymphocyte count, (1.1–3.2)×109/L | 1.26 (0.83,1.72) | 0.96 (0.62,1.34) | 1.47 (0.86,1.92) | 1.5 (1.26,1.63) | 0.149 |
| Hemoglobin, (115–150)g/L | 132.0 (113.5,140.5) | 127 (95,147) | 134.5 (120.75,137.5) | 141 (113,154) | 0.471 |
| D-dimer, (0–1)ug/mL | 0.88 (0.26,2.39) | 1.24 (0.65,2.39) | 1.64 (0.18,5.11) | 0.28 (0.11,1.19) | 0.114 |
| Albumin, (40–55)g/L | 39.3 (33.8,43.75) | 36.85 (29.15,43.78) | 40.95 (33.88,44.73) | 40.8 (36.9,43.1) | 0.441 |
| Alanine aminotransferase, (9–50)U/L | 23.3 (12.1,33.3) | 27.25 (10.85,32.28) | 18.3 (12.48,31.25) | 26.6 (11.9,57.0) | 0.886 |
| Aspartate aminotransferase, (15–40)U/L | 26.4 (17.1,45.0) | 26.55 (21.33,36.15) | 32.95 (16.95,58.57) | 21.2 (16.7,35.1) | 0.758 |
| Serum creatinine, (57–111)umol/L | 71.3 (52.6,92.5) | 72.6 (65.0,144.48) | 68.4 (59.3,73.08) | 72.6 (65.0,85.0) | 0.856 |
| Creatine kinase, (38–174)U/L | 125.0 (69.45,182.5) | 147.7 (72.9,225.0) | 107.0 (60.75,152.88) | 88.5 (67.58,692.75) | 0.761 |
| Lactate dehydrogenase, (82–285)U/L | 237 (161.0，325.0) | 336.0 (186.0,420.0) | 232.0 (161.25,317.0) | 150.5 (132.75,406.25) | 0.094 |
| Blood glucose, (3.9–6.1)mmol/L | 5.81 (4.99,7.92) | 6.19 (5.1,8.33) | 7.15 (4.9,8.83) | 5.09 (4.67,5.81) | 0.249 |
| Brain natriuretic peptide, (<100)pg/ml | 120.9 (27.73,924.88) | 372.0 (84.12,13710.0) | 73.76 (16.53，229.15) | 96.0 (17.5，1030.4) | 0.095 |
NS group: New-onset seizure group without epilepsy history; RS group: recurrent seizure with epilepsy history; EH group: epilepsy history group.
P less than 0.05 was considered statistcally significant.